Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial
Journal article published in 2019 by
Joaquín Gavilá,
Mafalda Oliveira,
Tomás Pascual 
,
Jose Perez-Garcia,
Xavier Gonzàlez ,
Jordi Canes,
Laia Paré,
Isabel Calvo,
Eva Ciruelos,
Montserrat Muñoz,
Juan A. Virizuela,
Isabel Ruiz,
Raquel Andrés,
Antonia Perelló,
Jerónimo Martínez
and other authors.
,
Jose Perez-Garcia,
Xavier Gonzàlez ,
Jordi Canes,
Laia Paré,
Isabel Calvo,
Eva Ciruelos,
Montserrat Muñoz,
Juan A. Virizuela,
Isabel Ruiz,
Raquel Andrés,
Antonia Perelló,
Jerónimo Martínez
and other authors.
This paper is made freely available by the publisher.
Full text: Download
Data provided by 